Our previous studies demonstrated that PML is a growth suppressor that suppresses oncogenic transformation of NIH/3T3 cells and rat embryo fibroblasts. PML is a nuclear matrix-associated phosphoprotein whose expression is regulated during the cell cycle. To further understand the mechanism of the effect of PML on HeLa cells, expression of cell cycle-related proteins in HeLa/PML and parental HeLa cells was analyzed. We found that Rb phosphorylation was significantly reduced in PML stable clones. Expression of cyclin E, Cdk2 and p27 proteins was also significantly reduced. These studies indicate that PML affects cell cycle progression by mediating expression of several key proteins that normally control cell cycle progression. These results further extend our current understanding of PML function in human cells and its important role in cell cycle regulation.
Introduction
The PML gene was originally identified by cloning the translocation breakpoint of t(15;17)(q22;q12), a consistent feature of acute promyelocytic leukemia (APL*) (1) (2) (3) . The translocation causes fusion of the PML and retinoic acid receptor-α (RARα) genes, from which fusion transcripts PML-RARα and RARα-PML have been transcribed (4) (5) (6) (7) (8) (9) . The PML-RARα fusion protein contains most of the functional domains of the PML and RARα proteins and has been shown to play an important role in APL leukemogenesis (10) . Since treatment of APL patients with retinoic acid (RA) leads to complete clinical remission, it is believed that disruption of the RARα gene by the translocation plays a role in leukemogenesis. However, evidence indicates that when the myeloid leukemia cell line HL-60 loses its RA inducibility, this inducibility can be completely restored by other forms of RAR or retinoid X receptor (RXR) (11) , suggesting that the loss of RARα function in APL cells may not be a critical event in leukemogenesis. Although the molecular mechanism by which the PML-RARα fusion protein exerts its leukemogenic effect as well as the highly specific therapeutic role of RA in the disease are still poorly understood, it has been shown that the fusion protein PML-RARα is able to form a heterodimer with PML or RXR (10, (12) (13) (14) . Formation of such non-functional heterodimers may disrupt the normal function of PML in APL. It has also been shown that the normal speckled nuclear pattern of expression of PML is dominantly affected by PML-RARα fusion protein in a RA-reversible fashion (8, (12) (13) (14) . In addition, our previous study demonstrated that PML-RARα inhibited the growth suppressor function of PML (15) . Thus the fusion protein may be a dominant negative inhibitor of PML.
PML has been shown to be involved in transcription regulation in a promoter-specific manner (15, 16) . In cotransfections PML suppressed transcription of the MDR1 and EGFR promoters (15) , and stimulated transcription of the promoters of progesterone and other steroid hormone receptors (16) . PML belongs to a novel family of proteins characterized by the presence of a C 3 HC 4 RING finger, one or two additional Cys/His-rich motifs and an α-helical coiled-coil region (17, 18) . The RING domain of PML is probably involved in proteinprotein interactions, a feature which may be common to other RING finger domains (19) . The C-terminus of the predicted PML protein consists of a Pro/Ser-rich region, which suggests that PML may be a phosphoprotein and a substrate for serine/ threonine protein kinase and/or phosphatase (7). We recently confirmed that PML is associated with the nuclear matrix, that it is a tyrosine/serine phosphoprotein when transiently expressed in NIH/3T3 cells (20) and that its expression is cell cycle related (20) . The PML protein has been shown to be part of nuclear multiprotein complexes or nuclear bodies designated PML oncogenic domains (PODs), which are distinct from snRNPs and nucleoli (12) (13) (14) 21, 22) . The function of PML nuclear bodies is at present unknown. In APL cells expression of PML-RARα fusion protein alters the distribution and size of these nuclear bodies and disrupts their normal pattern (12) (13) (14) . Interestingly, induction of differentiation in these cells after treatment with RA reverses these changes and restores a normal PML nuclear body staining pattern (12, 14) , a response not seen in RA-resistant APL cells. This observation suggests that disruption of the PML gene by 15;17 translocation is directly involved in the leukemogenic process.
Previously we convincingly demonstrated that PML is a growth suppressor (15), a finding recently confirmed by Koken et al. (23) . In brief, PML suppresses transformation of rat embryo fibroblasts by cooperative oncogenes and transformation of NIH/3T3 cells by the activated neu oncogene and its transduction into APL-derived NB4 cells leads to a decrease in soft agar colony formation. In a recent study we showed that PML could suppress neu expression and block signaling events associated with activated neu (24) . It has been shown that the PML gene is not expressed or only at low levels in normal tissues but displays an altered expression pattern during human oncogenesis (23) . A significant increase in PML levels was found in human epithelial tumors and, interestingly, PML expression was lost when the tumor turned invasive (23) . Another study demonstrated that the level of PML expression is considerably enhanced in inflammatory tissues and in tumorous states (25) . All the above evidence suggest that elucidation of the functional role of PML will not only help us understand leukemogenesis but also the genesis of other types of human cancers.
To further investigate the biological function of PML and its role in cell growth control, we established and studied clones that stably overexpress PML in HeLa cells. We found that constitutive overexpression of PML in HeLa cells significantly reduced their growth rate, clonogenicity on soft agar and tumorigenicity in nude mice. Our study demonstrated that PML suppresses cell growth by prolonging the G1 phase of the cell cycle. Our data also show that overexpression of PML affects expression of several key proteins that normally mediate cell cycle progression.
Materials and methods

Cell culture and gene transfection
HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% bovine calf serum (Gibco BRL, Gaithersburg, MD). To select stable transfectants of PML in HeLa cell cultures, the expression plasmid pSG5PML (15) was co-transfected with pSV2neo into HeLa cells by lipofectaminemediated gene transfer according to the manufacturer's recommended procedure (Gibco BRL) (pSG5PML carries the full-length PML cDNA driven by the SV40 early promoter). Cells were then selected in the presence of 800 µg/ml G418 for 3 weeks, after which resistant colonies were expanded for further analysis.
Western blot analysis and immunofluorescence staining
Western blot analysis and immunofluorescence staining of the stable transfectants of PML were carried out as described in our previous report (20) . Briefly, HeLa/PML clones were cultured to confluence in 100 mm dishes. Nuclear protein was isolated for analysis of PML expression by Western blotting. Cells were washed twice with 1ϫ TD buffer (100 mM NaCl, 20 mM KCl, 0.5 mM Na 2 HPO 4 , 20 mM Tris-HCl, pH 7.45) and resuspended in 1.5 ml 1ϫ TD buffer with a rubber policeman. Cells were centrifuged at 500 g for 10 min at 4°C and then resuspended in buffer A (100 mM NaCl, 50 mM KCl, 0.1 mM EDTA, 20 mM Tris-HCl, pH 7.5, 10% v/v glycerol, 0.2% v/v NP-40, 0.1% v/v Triton X-100, 1 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin). The cell suspension was incubated on ice for 10 min and centrifuged at 500 g for 10 min at 4°C to pellet the nuclei. Pelleted nuclei were resuspended in buffer A and SDS was added to 1%. The nuclear protein samples were mixed 1:1 with 2ϫ SDS sample buffer (0.1 mol/l Tris-HCl, pH 6.8, 0.2 M dithiothreitol, 4% w/v SDS, 0.2% w/v bromophenol blue, 20% v/v glycerol) and subjected to 8% SDS-PAGE. Proteins were then transferred to nitrocellulose filters (Schleicher & Schuell, Keene, NH) in buffer containing 25 mM Tris, 192 mM glycine and 20% methanol (v/v). Filters were blocked with 1ϫ phosphate-buffered saline (PBS) containing 5% non-fat dried milk for 1 h. The filters were then incubated for 2 h with a 1:1000 dilution of PML antibody raised against GST-PML fusion protein in rabbits. Immunodetection was performed using the ECL Western blotting detection system (Amersham Corp., Arlington Heights, IL). Immunofluorescence staining of the PML protein was performed using the PML antibody raised against GST-PML fusion protein as described previously (20) . Monoclonal antibodies against p16, p21, p27, cyclin E, cyclin D1 and cyclin A were obtained from Oncogene
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Research Products (Cambridge, MA). The monoclonal antibodies against Cdk2, actin and Rb were purchased from Santa Cruz Biotechnology (Santa Cruz, CA), Boehringer Mannheim Corp. (Indianapolis, IN) and Pharmingen (San Diego, CA) respectively.
In vitro growth rate assay
The in vitro growth rate of PML-transfected HeLa clones was assessed using the crystal violet assay as described by Gleave et al. (26) . Cells (1ϫ10 4 /well) from individual clones were plated in 24-well culture plates in 1 ml culture medium. The number of cells was determined at 24 h intervals. Cell proliferation was analyzed by measuring [ 3 H]thymidine incorporation. A total of 1ϫ10 4 cells were plated in triplicate in 24-well plates and cultured in complete medium. [ 3 H]Thymidine (2 mCi) was added to each well at 24, 48 and 72 h and left to incubate for an additional 2 h at 37°C. Cells were washed with PBS and harvested by lysing with 0.1% SDS. Radioactivity of the incorporated thymidine was determined in a scintillation counter.
Determination of population doubling time
Cells were plated at 5ϫ10 4 /well in a 12-well plate in triplicate and cultured in complete medium. The number of viable cells was determined by trypan blue exclusion assay and counted at daily intervals for 4 days.
Soft agar colony-forming assay
Soft agar colony-forming assays were performed at least in triplicate. Cells (1.5ϫ10 3 ) from each clone were plated onto 60 mm culture dishes in medium containing 0.35% agar overlying a 0.7% agar layer. Cells were cultured at 37°C for 14 days in a humidified CO 2 incubator. Colonies were visualized by staining with 0.1% p-iodonitrotetrazolium violet (Sigma Chemical Co., St Louis, MO).
Cell synchronization
HeLa and HeLa/PML cells were synchronized at the G1/S phase boundary by the double thymidine block protocol as described in a previous report (20) . Briefly, cells were cultured in the presence of 2 mM thymidine in DMEM with 10% bovine fetal serum for 14 h. Cells were then washed and cultured in regular medium for 10 h and again cultured for 14-16 h in the presence of 2 mM thymidine. Cells were released from the G1/S block by washing with PBS and cultured in regular medium. Cells were harvested at various time points as shown in Figures 5 and 6 for flow cytometric analysis.
Flow cytometric analysis
For analysis of DNA content by flow cytometry, cells from exponential and synchronized cultures were fixed for at least 24 h in 70% ethanol, washed twice with PBS and resuspended in PBS containing 50 µg/ml propidium iodide (Sigma Chemical Co.) and 20 µg/ml DNase-free RNase A. Cells were left in the dark overnight before being analyzed in a FACSCAN flow cytometer equipped with a double discriminator and LYSYS II and CELLFIT software (Becton-Dickinson & Co., San Jose, CA).
Results
Establishment of PML stable transfectants in HeLa cells
In a previous study we demonstrated that PML suppresses cell growth and oncogenic transformation of REF and NIH/3T3 cells. To further study the consequences of increased expression of PML in human tumor cells, the PML expression plasmid pSG5PML (15) and pSV2neo were co-transfected into HeLa cells. A weak PML nuclear speckled pattern was detected in the parental HeLa cells by immunofluorescence staining. After transfection, stable cells were selected in G418 and neomycinresistant colonies were isolated and expanded. Four clones, designated HeLa/PML1, HeLa/PML2, HeLa/PML3 and HeLa/ PML4 respectively, were selected for further study. Western blot analysis showed that all of these clones expressed a high level of the 90 kDa PML protein. The PML protein was undetectable in the parental HeLa and HeLa/pSG5 cells (a negative control) by Western blotting ( Figure 1A) .
Immunofluorescence staining was performed to confirm overexpression of PML protein in stable clones. As shown in Figure 1C , both the number and intensity of PML nuclear speckled signals were significantly increased in HeLa/PML cells. Our results further showed that overexpressed PML protein was associated with the nuclear matrix (data not shown), in agreement with its normal cellular localization as previously reported (20) .
Effect of PML overexpression on cell growth
We had previously shown that PML can repress the growth of B104-1-1 cells (NIH/3T3 cells transformed by the activated neu oncogene). Now, to further test the effect of increased expression of PML on HeLa cell growth, the growth characteristics of HeLa cells and HeLa/PML clones were determined as described in Materials and methods. As shown in Figure  2A , PML-transfected clones grew significantly more slowly than the parental HeLa and HeLa/pSG5 (mock control) cells. The parental HeLa and HeLa/pSG5 cells incorporated high levels of [ 3 H]thymidine, thought a noticeably lower DNA synthesis rate was found in all of the PML-transfected cells ( Figure 2B ). 
Suppression of clonogenicity and tumorigenicity of HeLa cells by PML overexpression
To investigate the effect of increased expression of PML protein on anchorage-independent growth, we assayed four HeLa/PML clones and HeLa cells for their ability to grow on soft agar. The HeLa/PML clones formed significantly fewer and smaller colonies than did the parental HeLa and mock control cells (Figure 3 ). Since HeLa cells have been shown to be highly tumorigenic when injected into nude mice (27) , we sought to determine whether overexpression of PML in HeLa cells suppresses their tumorigenicity. Cells (10 6 ) from control and two HeLa/PML clones were injected s.c. into the flanks of athymic nude mice and tumor volume and weight subsequently measured. As shown in Table I , PML overexpression did not completely suppress tumor formation in nude mice but significantly reduced tumor size and weight in mice injected with HeLa/ PML clones.
Cell cycle progression of HeLa/PML clones
To investigate how PML affects cell growth control, we examined several parameters correlated with cell growth and cell cycle progression. We performed flow cytometry analysis on exponentially growing cell cultures. As summarized in (Table II) . We also used the flow cytometry data and the exponential doubling times to calculate the approximate length in hours of each of these three phases of the cell cycle in various cell lines (Table II) . The S phase for both the control and HeLa/PML clones lasted 7 h and the G2/M phases~2 h. On the other hand, the G1 phase for the two HeLa/PML clones was longer than for the control cells (16 versus 12 h ). Thus the increased doubling time of the HeLa/PML clones appeared to be due mainly to a lengthening of the G1 phase.
We further synchronized the parental HeLa, HeLa/pSG5 and HeLa/PML clones by double thymidine block and then determined the duration of cell cycle phases by monitoring [ 3 H]thymidine incorporation ( Figure 4) . As expected, thymidine incorporation by HeLa/PML clones revealed a significant reduction in DNA synthesis in S phase and a longer duration of the cell cycle, most likely the result of a prolonged G1 phase, as shown in Table II. 2066
Distribution of cell cycle phases of HeLa/pSG5 and HeLa/ PML cells at various time points after release from a double thymidine block
To confirm our finding that overexpression of PML causes a G1 arrest, HeLa/pSG5 and HeLa/PML cells were synchronized at G1/S by double thymidine block. Distribution of cells at G1, S and G2/M phases at various time points after release from thymidine block were determined by flow cytometry as described in Materials and methods. As shown in Figure 5 , the majority of cells were arrested in G1 phase during double thymidine block. Cell cycles in both cell types were synchronized at S, G2/M and G1 phases 4, 8 and 12 h after release from the thymidine block respectively ( Figure 5 ). After 18 h the majority of HeLa/pSG5 cells had entered S phase (70%), however, the majority of HeLa/PML cells remained in G1 (61%). After 22 h a significant portion of HeLa/pSG5 cells had entered G2/M but most HeLa/PML cells still remained in G1/S ( Figure 5) . A similar experiment was also performed on another HeLa/PML clone (HeLa/PML4) and comparable results were obtained (data not shown).
Results of the above study are summarized and shown in Figure 6 . Figure 6B shows the percentage of cells in G1 phase plotted against the time of cell cycle progression. This result clearly shows a prolongation of G1 phase of HeLa/PML cells compared with the HeLa/pSG5 control. Figure 6A shows the percentage of cells in S phase during cell cycle progression. This result clearly shows an elongation of cell cycle duration in the HeLa/PML cells, which is in agreement with the result of [ 3 H]thymidine incorporation as shown in Figure 4 . These studies thus confirmed that overexpression of PML prolongs the G1 phase of the cell cycle and lengthens cell cycle duration.
Expression of cell cycle-related proteins in HeLa/PML and HeLa cells
To understand the molecular mechanism of the effects of PML on HeLa cells, expression of several cell cycle-related proteins in HeLa/PML and HeLa cells was analyzed by Western blotting. This analysis was performed using total proteins isolated from each cell type, which had been cultured to reach a cell density of 60-70% confluency. Results as shown in Figure 7 indicate that expression of several cell cycle-related proteins, including Cdk2, cyclin E and tumor suppressor protein p27, were significantly reduced in both HeLa/PML stable clones compared with the parental HeLa cells. Expression of these proteins in HeLa/pSG5 cells was also tested and found to be similar to that of the parental HeLa cells (data not shown). Our result also demonstrated that phosphorylation of Rb was significantly reduced in HeLa/PML clones (lanes 1 and 2). We have also analyzed expression of cyclin D1, cyclin A, tumor suppressors p21 and p16 and c-myb in HeLa/PML clones but failed to detect any significant changes in their expression. These results suggest that PML-induced growth suppression and G1 elongation in HeLa cells could be directly associated with hypophosphorylation of Rb and down-regulation of cyclin E/Cdk2.
Discussion
In a previous study we demonstrated that disruption of the normal function of PML, a growth suppressor gene, is a critical Western blotting was performed as described in Materials and methods using antibodies against Rb, cyclin E (cycE), Cdk2, p27 and other cell cycle-related proteins. The same filters were stripped and reprobed with antibody against actin to monitor the quantity of protein loaded on each lane (lower panels). event in APL leukemogenesis (15) . More recent reports have confirmed this and demonstrated further that PML has growth suppressive and anti-oncogenic properties and displays an altered expression pattern during human oncogenesis (23) . We have previously shown that PML suppresses the oncogenic transformation of neu-transformed NIH/3T3 cells and tumorigenicity of B104-1-1 cells (NIH/3T3 cells transformed by the activated neu oncogene) (24) . Meanwhile, others have shown PML protein to be dramatically increased in inflammatory and neoplastic human tissues (25) . Finally, it has been shown that PML expression may reflect human oncogenic status, that PML levels gradually decrease as lesions of human epithelial tumors progress to a more aggressive carcinoma and that PML expression is lost when such tumors turn invasive (23) . This evidence suggests that the involvement of PML in malignant transformation is not restricted to APL but may be involved in other types of human cancer.
In the present study we stably overexpressed PML protein in the HeLa cell line and further demonstrated that increased PML expression leads to decreased cell growth and tumorigenicity in vitro and in vivo. These findings support our previous finding that PML plays an important role in the control of cell growth, as a growth suppressor (15, 24) . In this study the growth and proliferation rates of cells overexpressing PML significantly decreased, as determined by their growth curves and thymidine incorporation. The reduced growth potential of the PML-transfected cells was also reflected in a dramatically decreased size and number of soft agar colonies (Figure 3) . Stably elevated PML expression also led to significantly reduced tumor size and to delayed tumor formation.
Recent studies have demonstrated that the cell cycle can be regulated positively or negatively. The negative regulators, referred to as tumor suppressors (e.g. Rb, p53 and p16), play an essential role in the control of cell proliferation by being directly involved in control of the cell cycle (28) . Negative regulation of cell growth is often lost in malignant cells, whose control of cell proliferation is deranged, and this eventually leads to the development of a tumor. In a previous report we found that the number of PODs in HeLa cells is cell cycle related. The highest number of PODs was found in the G1 phase. In the present study we investigated whether PML plays a role in cell cycle control. We found that overexpression of PML in HeLa cells can affect cell cycle progression. For example, it resulted in a longer G1 phase and an increase in the doubling time of HeLa cells versus controls. Analysis of expression of cell cycle-related proteins in HeLa/PML demonstrated that both Cdk2 and cyclin E proteins were significantly reduced in PML-overexpressing cells. These cell cycle-associated kinases have been documented as involved in phosphorylation of Rb during the G1 to S transition. As shown in Figure 7 , phosphorylation of Rb protein was indeed significantly reduced in the two HeLa/PML clones tested. This study provides direct evidence indicating that PML suppresses growth and tumorigenicity of HeLa cells by affecting expression of cell cycle regulatory proteins.
In addition to the effect of PML in cell cycle control, we have also examined the effect of PML on apoptosis of HeLa cells. The results of this study indicate that stable overexpression of PML did not affect apoptosis of these cells. Taken together, our results (i) indicate that increased expression of PML in HeLa cells markedly inhibits cell growth and (ii) suggest that this is due to prolongation of G1 phase and the resulting increase in doubling time. In addition to the effect of PML on HeLa cells, we have recently examined the effect of PML overexpression on several human tumor cell lines. These include the breast cancer cell lines SK-BR-3 and 2068 MCF-7, prostate cancer cell lines LNCaP, PC-3 and DU145 and ovarian cancer cell line SK-OV-3. We found that PML significantly suppressed their growth rate and clonogenicity on soft agar (unpublished results). These studies indicate that PML suppresses growth of a wide variety of human cancer cell lines, which is consistent with the findings presented in this report that overexpression of PML causes an elongation of G1 in HeLa cells. Recently recombinant PML-adenovirus has been produced in our laboratory and we showed that overexpression of PML in human primary fibroblasts by adenovirus-mediated gene transfer resulted in G1 arrest (unpublished observation). Overexpression of other growth suppressors, e.g. p53, p 21 /CIP1 and p 16 /INK4a, has also been shown to cause G1 arrest (29) (30) (31) . Our findings strongly support a role of PML in cell cycle control.
The biological function of many important cellular regulatory proteins is regulated by phosphorylation/dephosphorylation. For example, the phosphorylation status of Rb is tightly regulated during the cell cycle (32, 33) . PML is a growth/ transformation suppressor whose expression is cell cycle related (15, 20) . Our most recent study demonstrated that PML is a substrate of a cyclin/Cdk kinase and its phosphorylation pattern is cell cycle dependent (unpublished results). Therefore, to further understand the biological function of PML it will be important to further elucidate the phosphorylation status of PML during the various phases of the cell cycle.
